Administration of an antibody against IL-6R or genetic ablation of IL-6 significantly improved survival while reducing muscle wasting, whereas treatment with exogenous IL-6 resulted in muscle wasting in cancer-free mice [51,52,53]. The gene discussed is IL6; the disease is cancer.